secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2025-08-18T23:59:59+00:00
Accession:  0001641172-25-024614
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity Technologies appoints Roberto Rios and John Oppenheimer to board; Gary Rubin resigns
--------------------------------------------------------------------------------

- Roberto Rios (CPA) and John J. Oppenheimer (M.D.) appointed to Board, each term expiring at 2026 annual meeting.
- Gary Rubin resigned from Board and Nominating Committee effective Aug. 12, 2025, not due to any disagreement.
- Rios appointed Chair of Audit Committee and member of Compensation Committee; Oppenheimer on Nominating and Governance Committee.
- Jamie Platt appointed to Audit Committee and as Chair of Nominating and Governance Committee; Robert Anderson on Compensation Committee.
- New directors bring expertise in finance (Rios) and clinical respiratory research (Oppenheimer) to support CyPath Lung sales and pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000164117225024614/0001641172-25-024614-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000164117225024614/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-024614

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer